Corey Williams - February 1,4: The Company is in the process of manufacturing clinical trial materials and expects to commence enrollment in the first clinical study of LTX, Study AP-LTX, later in the first quarter of
RSS Pain Management Therapeutics Market Intelligence Study for Comprehensive Insights The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate.
In addition to this, a massive geriatric population susceptible to arthritis, nerve damage, neuropathy, and joint pain is also boosting the market for pain management therapeutics.
Overview Pain management therapeutics comprise various methods to ease varied degrees of pain among patients and improve their quality of life. Pharmaceutical therapeutics are usually the first line of treatment for pain management and if this does not work, patients opt for other methods such as pain managing devices, physiotherapy, and chiropractic therapy.
Pain management therapeutics can be categorized into antidepressants, anticonvulsants, opioids, anesthetics, antimigraine agents, non-steroidal anti-inflammatory drugs NSAIDSand non-narcotic analgesics. Various drugs are used for the management of different kinds of pain, such as fibromyalgia, neuropathic pain, arthritic pain, chronic back pain, post-operative pain, migraine, and cancer-related pain.
A common trend that has been observed among patients is the consumption of over-the-counter OTC drugs rather than prescription drugs. Request Sample Copy of the Report https: Trends The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate.
Supplementing market growth are favorable regulatory scenarios in many developed countries around the world. However, as more and more patients opt for generic pain management drugs, the branded segment has been suffering a major setback.
Moreover, the patent expiries of a number of blockbuster drugs will have a significant impact on the overall market for pain management therapeutics. Request TOC of the Report https: Market Potential Despite the fact that leading brands are nearing a point of saturation, the pain management therapeutics market possesses strong potential for growth, particularly for smaller players.
For instance, looking to expand its footprint in the global market as well as strengthen its U. Purdue Pharma, headquartered in Connecticut, U. Pain Management Therapeutics Market: North America and Europe hold the largest share in the overall market and are slated to continue their dominance throughout the forecast period.
The rising consumption of advanced pain management drugs and the availability of well-established and sophisticated healthcare infrastructure are the key factors driving the North America and Europe pain management therapeutics market.
Asia Pacific is an immensely lucrative region and a number of players are looking to expand their operations in the many emerging countries in the region. This can be attributed to strong economic growth in nations such as China, India, Malaysia, and Japan, rising investments in the healthcare industry in these countries, and the increasing affordability of the population.
Get a discount https: Competitive Analysis There are a host of generic as well as branded drug manufacturers in the global pain management therapeutics market. Although companies producing branded pain management therapeutics have a strong foothold in the market, the market is actually dominated by generic drug manufacturers, giving small- and medium-scale players immense scope for growth.
About TMR Research TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today's supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients' conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others.
With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, A safety assessment of LIMITX Hydromorphone will be made from both study cohorts.
Acura expects topline study results from Study AP-LTX to be available in the first half of OHR (Squalamine) Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD. NEW YORK, Jan. 05, (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported topline data from the MAKO study which did not meet its primary efficacy endpoint.
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc. Read More». Ceratosaurus was a theropod dinosaur in the Late Jurassic, around million years barnweddingvt.com genus was first described in by American paleontologist Othniel Charles Marsh based on a nearly complete skeleton discovered in Garden Park, Colorado, in rocks belonging to the Morrison barnweddingvt.com and , a partial specimen from the Lourinhã Formation of Portugal was described, providing.
The 'Global and Chinese Methadone Industry, Market Research Report' is a professional and in-depth study on the current state of the global Methadone industry with a focus on the Chinese market.
Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January Read more about it here. December. Monday. Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors. Read more about it here. View All Press.